TGTX - TG Therapeutics Inc. (TGTX) Q1 2024 Earnings Call Transcript
2024-05-02 22:21:08 ET
TG Therapeutics, Inc. (TGTX)
Q1 2024 Earnings Conference Call
May 01, 2024 08:30 AM ET
Company Participants
Jenna Bosco - Senior Vice President of Corporate Communications
Michael Weiss - President and Chief Executive Officer
Adam Waldman - Chief Commercialization Officer
Sean Power - Chief Financial Officer
Conference Call Participants
Michael DiFiore - Evercore ISI
Edward White - H.C. Wainwright
Roger Song - Jefferies
Matthew Kaplan - Ladenburg Thalmann
Mayank Mamtani - B. Riley Securities, Inc.
Prakhar Agrawal - Cantor Fitzgerald
Noah Eisenberg - JPMorgan
Corinne Jenkins - Goldman Sachs Group, Inc.
Presentation
Operator
Greetings, and welcome to the TG Therapeutics Conference Call and Webcast. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Jenna Bosco. Thank you, Jenna. You may begin.
Jenna Bosco
Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the first quarter 2024 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer.
Following our safe harbor statement, Mike will provide an overview of our recent corporate development, Adam will share an update on our commercialization efforts, and Sean will give an overview of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I'd like to remind everyone that we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our anticipated future operating and financial performance, including sales performance, projected regulatory or clinical milestones, revenue guidance, development plans and expectations for our marketed products....
TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript